This article explains how GLP-1 receptor agonist drugs such as semaglutide (Ozempic, Wegovy) and liraglutide promote weight loss in people with type 2 diabetes and obesity. A literature review suggests these drugs work through multiple mechanisms beyond insulin stimulation, including slowing gastric emptying and increasing satiety. Research is also exploring potential reduced risks of cancer and cardiovascular disease.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.